ChromeMate® Reduces Vascular Inflammation

SAN FRANCISCO—ChromeMate®, InterHealth Nutraceutical’s patented niacin-bound chromium complex, was found to significantly reduce vascular inflammation, according to a recent unpublished study presented at the American Diabetes Association’s 68th Annual Scientific Session, June 6 to 10 in San Francisco. The study was funded by the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH). The eight-week study supplemented 400 mcg of chromium (III) from ChromeMate or chromium picolinate per kg of body weight to the diet of obese Zucker diabetic rats. In comparison to the animal control group, the ChromeMate group experienced significantly lower total cholesterol and triglycerides than the chromium picolinate group. Levels of TNF-a, MCP-1, RBP-4 were also lower in the ChromeMate group than the control group;the chromium picolinate group did not experience any reduction in those markers.

“Results of this study further confirm a comprehensive body of evidence that demonstrates the cardiovascular benefits of ChromeMate,” stated Paul Dijkstra, CEO, InterHealth. “ChromeMate is also highly effective in helping maintain healthy blood sugar levels and body weight, which is important for people with diabetes. Given the close link between diabetes and cardiovascular disease, ChromeMate represents a triple benefit in promoting good health.”

www.InterHealthusa.com